1 Market Overview

• 1.1 Product Overview and Scope
• 1.2 Market Estimation Caveats and Base Year
• 1.3 Market Analysis by Type
  • 1.3.1 Overview: Global Surufatinib Consumption Value by Type: 2021 Versus 2025 Versus 2032
  • 1.3.2 Hospital
  • 1.3.3 Retail Pharmacy
  • 1.3.4 Online Pharmacy
• 1.4 Market Analysis by Application
  • 1.4.1 Overview: Global Surufatinib Consumption Value by Application: 2021 Versus 2025 Versus 2032
  • 1.4.2 Neuroendocrine Tumor
  • 1.4.3 Anti-angiogenic Therapy
  • 1.4.4 Tumor Immune Microenvironment Modulation
  • 1.4.5 Others
• 1.5 Global Surufatinib Market Size & Forecast
  • 1.5.1 Global Surufatinib Consumption Value (2021 & 2025 & 2032)
  • 1.5.2 Global Surufatinib Sales Quantity (2021-2032)
  • 1.5.3 Global Surufatinib Average Price (2021-2032)

2 Manufacturers Profiles

• 2.1 HUTCHMED
  • 2.1.1 HUTCHMED Details
  • 2.1.2 HUTCHMED Major Business
  • 2.1.3 HUTCHMED Surufatinib Product and Services
  • 2.1.4 HUTCHMED Surufatinib Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
  • 2.1.5 HUTCHMED Recent Developments/Updates

3 Competitive Environment: Surufatinib by Manufacturer

• 3.1 Global Surufatinib Sales Quantity by Manufacturer (2021-2026)
• 3.2 Global Surufatinib Revenue by Manufacturer (2021-2026)
• 3.3 Global Surufatinib Average Price by Manufacturer (2021-2026)
• 3.4 Market Share Analysis (2025)
  • 3.4.1 Producer Shipments of Surufatinib by Manufacturer Revenue ($MM) and Market Share (%): 2025
  • 3.4.2 Top 3 Surufatinib Manufacturer Market Share in 2025
  • 3.4.3 Top 6 Surufatinib Manufacturer Market Share in 2025
• 3.5 Surufatinib Market: Overall Company Footprint Analysis
  • 3.5.1 Surufatinib Market: Region Footprint
  • 3.5.2 Surufatinib Market: Company Product Type Footprint
  • 3.5.3 Surufatinib Market: Company Product Application Footprint
• 3.6 New Market Entrants and Barriers to Market Entry
• 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

• 4.1 Global Surufatinib Market Size by Region
  • 4.1.1 Global Surufatinib Sales Quantity by Region (2021-2032)
  • 4.1.2 Global Surufatinib Consumption Value by Region (2021-2032)
  • 4.1.3 Global Surufatinib Average Price by Region (2021-2032)
• 4.2 North America Surufatinib Consumption Value (2021-2032)
• 4.3 Europe Surufatinib Consumption Value (2021-2032)
• 4.4 Asia-Pacific Surufatinib Consumption Value (2021-2032)
• 4.5 South America Surufatinib Consumption Value (2021-2032)
• 4.6 Middle East & Africa Surufatinib Consumption Value (2021-2032)

5 Market Segment by Type

• 5.1 Global Surufatinib Sales Quantity by Type (2021-2032)
• 5.2 Global Surufatinib Consumption Value by Type (2021-2032)
• 5.3 Global Surufatinib Average Price by Type (2021-2032)

6 Market Segment by Application

• 6.1 Global Surufatinib Sales Quantity by Application (2021-2032)
• 6.2 Global Surufatinib Consumption Value by Application (2021-2032)
• 6.3 Global Surufatinib Average Price by Application (2021-2032)

7 North America

• 7.1 North America Surufatinib Sales Quantity by Type (2021-2032)
• 7.2 North America Surufatinib Sales Quantity by Application (2021-2032)
• 7.3 North America Surufatinib Market Size by Country
  • 7.3.1 North America Surufatinib Sales Quantity by Country (2021-2032)
  • 7.3.2 North America Surufatinib Consumption Value by Country (2021-2032)
  • 7.3.3 United States Market Size and Forecast (2021-2032)
  • 7.3.4 Canada Market Size and Forecast (2021-2032)
  • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

• 8.1 Europe Surufatinib Sales Quantity by Type (2021-2032)
• 8.2 Europe Surufatinib Sales Quantity by Application (2021-2032)
• 8.3 Europe Surufatinib Market Size by Country
  • 8.3.1 Europe Surufatinib Sales Quantity by Country (2021-2032)
  • 8.3.2 Europe Surufatinib Consumption Value by Country (2021-2032)
  • 8.3.3 Germany Market Size and Forecast (2021-2032)
  • 8.3.4 France Market Size and Forecast (2021-2032)
  • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
  • 8.3.6 Russia Market Size and Forecast (2021-2032)
  • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

• 9.1 Asia-Pacific Surufatinib Sales Quantity by Type (2021-2032)
• 9.2 Asia-Pacific Surufatinib Sales Quantity by Application (2021-2032)
• 9.3 Asia-Pacific Surufatinib Market Size by Region
  • 9.3.1 Asia-Pacific Surufatinib Sales Quantity by Region (2021-2032)
  • 9.3.2 Asia-Pacific Surufatinib Consumption Value by Region (2021-2032)
  • 9.3.3 China Market Size and Forecast (2021-2032)
  • 9.3.4 Japan Market Size and Forecast (2021-2032)
  • 9.3.5 South Korea Market Size and Forecast (2021-2032)
  • 9.3.6 India Market Size and Forecast (2021-2032)
  • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
  • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

• 10.1 South America Surufatinib Sales Quantity by Type (2021-2032)
• 10.2 South America Surufatinib Sales Quantity by Application (2021-2032)
• 10.3 South America Surufatinib Market Size by Country
  • 10.3.1 South America Surufatinib Sales Quantity by Country (2021-2032)
  • 10.3.2 South America Surufatinib Consumption Value by Country (2021-2032)
  • 10.3.3 Brazil Market Size and Forecast (2021-2032)
  • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

• 11.1 Middle East & Africa Surufatinib Sales Quantity by Type (2021-2032)
• 11.2 Middle East & Africa Surufatinib Sales Quantity by Application (2021-2032)
• 11.3 Middle East & Africa Surufatinib Market Size by Country
  • 11.3.1 Middle East & Africa Surufatinib Sales Quantity by Country (2021-2032)
  • 11.3.2 Middle East & Africa Surufatinib Consumption Value by Country (2021-2032)
  • 11.3.3 Turkey Market Size and Forecast (2021-2032)
  • 11.3.4 Egypt Market Size and Forecast (2021-2032)
  • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
  • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

• 12.1 Surufatinib Market Drivers
• 12.2 Surufatinib Market Restraints
• 12.3 Surufatinib Trends Analysis
• 12.4 Porters Five Forces Analysis
  • 12.4.1 Threat of New Entrants
  • 12.4.2 Bargaining Power of Suppliers
  • 12.4.3 Bargaining Power of Buyers
  • 12.4.4 Threat of Substitutes
  • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

• 13.1 Raw Material of Surufatinib and Key Manufacturers
• 13.2 Manufacturing Costs Percentage of Surufatinib
• 13.3 Surufatinib Production Process
• 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

• 14.1 Sales Channel
  • 14.1.1 Direct to End-User
  • 14.1.2 Distributors
• 14.2 Surufatinib Typical Distributors
• 14.3 Surufatinib Typical Customers

15 Research Findings and Conclusion

16 Appendix

• 16.1 Methodology
• 16.2 Research Process and Data Source

According to our (Global Info Research) latest study, the global Surufatinib market size was valued at US$ 32.82 million in 2025 and is forecast to a readjusted size of US$ 67.39 million by 2032 with a CAGR of 5.8% during review period.
.In 2025, global surufatinib production reached approximately 12.6 million units.Surufatinib is an oral small-molecule multi-target tyrosine kinase inhibitor (TKI), primarily used for the treatment of neuroendocrine tumors (NETs). It exerts its effects by simultaneously inhibiting multiple signaling pathways, including vascular endothelial growth factor receptors (VEGFR), fibroblast growth factor receptors (FGFR), and colony-stimulating factor-1 receptor (CSF-1R), thereby providing dual anti-angiogenic and tumor immune-modulating activities, which suppress tumor growth and the immunosuppressive tumor microenvironment. Surufatinib is characterized by a multi-target synergistic mechanism, convenient oral administration, and broad-spectrum antitumor activity, making it clinically valuable in the treatment of advanced neuroendocrine tumors.
Surufatinib, as a multi-target tyrosine kinase inhibitor (TKI), operates within a relatively niche yet growing segment of the neuroendocrine tumor (NET) treatment market. With the increasing detection of NETs due to improved diagnostic methods and the advancement of precision medicine, the demand for targeted therapies continues to rise, providing a stable market foundation for surufatinib.From a competitive landscape perspective, targeted therapies and mTOR inhibitors such as Sunitinib and Everolimus currently dominate the market. However, surufatinib, with its multi-target mechanism acting on VEGFR, FGFR, and CSF-1R, as well as its differentiated advantage in modulating the tumor immune microenvironment, demonstrates competitive potential in specific patient populations.On the policy side, its inclusion in the national reimbursement drug list helps improve patient accessibility and promote market expansion, although healthcare cost-control measures and volume-based procurement policies continue to exert pressure on pricing. From a competitive standpoint, although treatment options for neuroendocrine tumors remain relatively limited, the continuous development of new targeted therapies and immunotherapy regimens is gradually intensifying competition. Therefore, the future market performance of surufatinib will depend on its progress in expanding indications (such as additional NET subtypes or other solid tumors), developing combination treatment strategies, and accumulating real-world evidence, as well as its overall competitive balance in terms of efficacy, safety, and cost.
This report is a detailed and comprehensive analysis for global Surufatinib market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Surufatinib market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Surufatinib market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Surufatinib market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Surufatinib market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Surufatinib
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Surufatinib market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include HUTCHMED, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Surufatinib market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Hospital
Retail Pharmacy
Online Pharmacy
Market segment by Application
Neuroendocrine Tumor
Anti-angiogenic Therapy
Tumor Immune Microenvironment Modulation
Others
Major players covered
HUTCHMED
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Surufatinib product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Surufatinib, with price, sales quantity, revenue, and global market share of Surufatinib from 2021 to 2026.
Chapter 3, the Surufatinib competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Surufatinib breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Surufatinib market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Surufatinib.
Chapter 14 and 15, to describe Surufatinib sales channel, distributors, customers, research findings and conclusion.